STOCK TITAN

Teladoc (TDOC) CAO sells shares, receives RSU and PSU grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Teladoc Health, Inc.’s Chief Accounting Officer, Joseph Ronald Catapano, reported a mix of stock sales, vesting, and new equity awards. He sold 1,333 shares of common stock at $5.117 per share, with a footnote stating the sale was made to cover tax withholding tied to vesting of his restricted and performance stock units.

On the equity award side, he received a grant of 15,000 restricted stock units, each representing a contingent right to one share of Teladoc common stock, and 465 performance stock units earned based on 2025 financial metrics, also convertible one-for-one into common shares. Footnotes state these awards generally vest one-third on the first anniversary of the grant or earning date, with the remainder vesting in eight substantially equal quarterly installments thereafter. Following these transactions, he directly owned 8,841 shares of common stock, plus outstanding RSU and PSU awards.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Catapano Joseph Ronald

(Last) (First) (Middle)
C/O TELADOC HEALTH, INC.,
155 E 44TH ST, SUITE 1700

(Street)
NEW YORK NY 10017

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/27/2026 M 3,333 A (1) 10,019 D
Common Stock 02/27/2026 M 155 A (2) 10,174 D
Common Stock 03/02/2026 S 1,333(3) D $5.117 8,841 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/27/2026 M 3,333 (4) (4) Common Stock 3,333 $0 6,667 D
Performance Stock Units (5) 02/27/2026 A 465(6) (6) (6) Common Stock 465 $0 465 D
Performance Stock Units (2) 02/27/2026 M 155 (7) (7) Common Stock 155 $0 310 D
Restricted Stock Units (8) 03/01/2026 A 15,000 (9) (9) Common Stock 15,000 $0 15,000 D
Explanation of Responses:
1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
2. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
4. On March 1, 2025, the reporting person was granted 10,000 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
5. Each performance stock unit represents a contingent right to receive one share of TDOC common stock.
6. Performance award amount determined based on metrics in respect of the issuer's 2025 financial results.
7. On March 1, 2026, the reporting person earned 465 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
8. Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
9. One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Remarks:
/s/ Adam C. Vandervoort, Attorney-in-Fact 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Teladoc (TDOC) CAO Joseph Catapano report?

He reported multiple transactions: an open-market sale of 1,333 Teladoc common shares at $5.117 per share and several equity award-related entries, including exercises of stock units and new grants of restricted and performance stock units that convert one-for-one into common shares.

How many Teladoc (TDOC) shares did the CAO sell and why?

Joseph Catapano sold 1,333 shares of Teladoc common stock at $5.117 per share. A footnote explains the shares were sold specifically to cover the tax withholding obligation arising from the vesting of his restricted stock unit and performance stock unit awards, not for discretionary cash-raising.

What new restricted stock unit awards did the Teladoc CAO receive?

He received an award of 15,000 restricted stock units, each representing a contingent right to one Teladoc common share. Footnotes describe a vesting schedule where one-third vests on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments afterward.

What performance stock units were reported in the Teladoc Form 4?

The filing shows he earned 465 performance stock units, each giving a contingent right to one Teladoc common share. Footnotes state the performance amount was determined using 2025 financial metrics, and these units vest one-third on March 1, 2026, with the rest in eight quarterly installments.

How did the Teladoc CAO’s common stock holdings change after these transactions?

After exercising stock units into common shares and then selling some shares for tax withholding, his directly held Teladoc common stock position was reported as 8,841 shares. In addition, he holds separate restricted stock unit and performance stock unit awards that may convert into common shares over future vesting dates.

How do Teladoc restricted and performance stock units convert into common stock?

Footnotes explain that both restricted stock units and performance stock units convert into Teladoc common stock on a one-for-one basis. Each unit represents a contingent right to receive one share, subject to meeting vesting schedules and, for performance units, achievement of specified financial performance metrics.
Teladoc Health Inc

NYSE:TDOC

TDOC Rankings

TDOC Latest News

TDOC Latest SEC Filings

TDOC Stock Data

933.51M
173.38M
Health Information Services
Services-offices & Clinics of Doctors of Medicine
Link
United States
NEW YORK